“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting - Episode 3

Third and Subsequent Line Options for Multiple Myeloma

January 29, 2021
Ajai Chari, MD, Mount Sinai Hospital

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center

Saad Z. Usmani, MD, FACP, Levine Cancer Institute

Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Experts in multiple myeloma discuss third-line and subsequent options for treating multiple myeloma, and BCMA-targeted approaches presented at the ASH 2020 Virtual Meeting.

Data from the following presentations are discussed:

  • CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. (Madduri, ASH 2020 Abstract 177)

  • Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. (Alsina, ASH 2020 Abstract130)

  • Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. (Mailankody, ASH 2020 Abstract129)